Her2-specific CAR T cells demonstrated preclinical efficacy in several tumor models, including a patient-derived xenograft (PDX) model using patient-autologous T cells to minimize allogenic reactions [102–106]. The gene discussed is ERBB2; the disease is neoplasm.